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OBJECTIVES: To assess the cost-effectiveness, from the UK
NHS perspective, of magnetic resonance angiography (MRA),
duplex ultrasound (DUS) and computed tomography (CT) com-
pared with contrast angiography (CA) in assessing the extent and
location of stenosis and subsequently formulating a treatment
plan for patients with peripheral arterial disease (PAD).
METHODS: A probabilistic decision tree was developed in order
to estimate the cost per QALY (in £2004) associated with each
diagnostic method for assessment of the whole leg, and the arter-
ies above and below the knee. Input parameters were obtained
from a systematic review, other published sources and expert
opinion. Lack of data to extrapolate the results to a longer period
led to consideration of a 1-year time horizon, therefore dis-
counting was not performed. RESULTS: DUS was the dominant
strategy for the assessment of the whole leg, with a cost per
QALY of £13,646. MRA appeared to be more cost-effective for
assessment of the arteries above the knee, with a cost-per-QALY
equal to £8628 with 2D-TOF MRA, and an incremental cost per
additional QALY equal to £37,024 when 2D-TOF MRA was
compared to DUS. For below the knee comparisons, results were
uncertain, with DUS being more likely to be cost-effective at
commonly accepted cost-per-QALY threshold values. CON-
CLUSIONS: The cost-effectiveness of the diagnostic tests was
dependent on the area of the leg being assessed, with DUS being
dominant for comparisons of the whole leg and cost-effective for
below the knee comparisons, and MRA being cost-effective for
above the knee assessments.
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OBJECTIVES: Drug eluting stents (DES) are more effective than
bare metal stents (BMS) in preventing angiographic and clinical
restenosis. Within this study the cost-effectiveness of sirolimus
(SES) and paclitaxel eluting stents (PES) compared to BMS was
estimated for a UK setting with data from a meta-analysis.
METHODS: A probabilistic Markov model was constructed.
The model includes events observed in clinical trials (MI, revas-
cularisation, CABG) and the health states heart failure and
stroke. The meta-analysis data comprised 3-year follow-up data
from randomized controlled trials. Probability distributions were
ﬁtted to all transition probability, cost and quality of life (QoL)
parameters. Univariate sensitivity analysis was performed on
several parameters. Effects and costs were discounted at 3%, the
time horizon was 3 years and the number of stents was 1.27 per
patient. A health care perspective was adopted. QoL data was
obtained from published studies. RESULTS: The incremental
costs for SES patients are €712 (95% CI: −2431–1715) and
€1101 (95% CI: 150–1493) for PES patients. DES yield less
QALYs than BMS with −0.0156 incremental QALYs (95% CI:
−0.2652–0.2302) per SES patient and −0.0077 incremental
QALYS (95% CI: −0.0777–0.06643) per PES patient compared
to BMS patients. At a threshold level of Euros 50’000 per QALY
the incremental net monetary beneﬁt per SES patient is €−1492
(95% CI: −14213–10766) and €−1484 (95% CI: −5004–2273)
per PES patient. At the same threshold level SES have a 35%
probability of being cost-effective, PES have a probability of
17% of being cost-effective. CONCLUSIONS: Three-year
follow up data show that DES are less effective than BMS when
mortality is taken into account. Given the higher costs per DES
patient, DES are dominated by BMS. Althoug DES show
favourable results over BMS concerning revascularisation rates,
they are not cost-effective.
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OBJECTIVE: To determine the presence of cardiovascular events
(CVEs) and their association with the main cardiovascular risk
factors (CVRFs) and resource utilization parameters (direct
costs) in subjects with chronic obstructive pulmonary disease
(COPD) in different Spanish primary care centers. METHODS:
A retrospective-multicenter design was adopted, with inclusion
of the patients seen for COPD (ICPC:R95) by four primary care
teams and two hospitals during 2004. The main measures were:
age-sex, cardiovascular antecedents (ischemic heart disease
[IHD], cerebrovascular accident, hypertension, dyslipidemia,
diabetes mellitus, smoking, obesity) and other co-morbidities,
clinical parameters (FEV1, BMI), resources utilization (comple-
mentary tests, pharmaceutical prescription, specialist referral,
physician visits, hospitalizations and emergency-room visits,
ambulatory care) and costs (semiﬁxed and direct). A logistic
regression analysis was made to ﬁt the model. The costs were
contrasted by covariance analysis (ANCOVA-marginal means).
Data were analyzed using SPSS-v12 and p values of <0.05 were
taken as the level of statistical signiﬁcance. RESULTS: Nine-
hundred patients were seen for COPD; mean age 70.4 ± 9.8 years
and 85.3% were males. Around 19.0% (n = 171) had undergone
a CVE (CI: 16.4–21.6%); 15.1% with IHD. The main CVRFs
were: 44.1%-hypertension, 36.2%-obesity, 31.9%-dyslipidemia,
23.6%-diabetes and 22.7%-smoking. The mean morbidity/
patient/year was 10.1 ± 4.2 with CVEs vs. 8.3 ± 4.3 (p = 0.000);
the clinical parameters studied (FEV1, BMI) showed no signiﬁ-
cance. The logistic model, corrected for age-sex and severity
identiﬁed as associated factors: diabetes mellitus (OR = 2.1; 
CI = 1.3–3.4; p = 0.001) and dyslipidemia (OR = 1.7; CI =
1.1–2.7; p = 0.002). Quantiﬁcation of unit cost/year/COPD was
€2793.22 ± 3166.30 (70.5% pharmaceutical expenditure). The
cost/year/patient-adjusted was €2847.22 (SE = 117.02) without
CVEs, versus €2563.66 (SE = 244.05) with CVEs, p = NS. CON-
CLUSIONS: The presence of CVEs associated with COPD is
high, causing an important co-morbidity, though without
increasing the global costs of the disease. Diabetes mellitus and
dyslipidemia are the main CVRFs associated; their prevention
could improve the disease outcomes. Further studies are needed
to conﬁrm the consistency of these results.
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OBJECTIVES: In The Netherlands, costs of statin use have
recently increased sharply compared to costs of other drugs. Yet,
several studies have established undertreatment and overtreat-
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ment with statins, suggesting a suboptimal use of resources. We
studied the drug costs associated with overtreatment and the
costs to eliminate undertreatment with statins in an elderly pop-
ulation. METHODS: Overtreatment and undertreatment with
statins were ascertained using current Dutch cholesterol man-
agement guidelines. Data were acquired from the Rotterdam
Study. This is a population-based prospective cohort study,
which started in 1990 with 7983 participants of at least 55 years
of age. This analysis focused on primary prevention of cardio-
vascular disease (CVD) excluding subjects with a history of car-
diovascular disease. To estimate patterns of medication use in
daily practice pharmacy records were obtained. RESULTS: From
the 3251 participants 464 (14%) were still alive on January 1st
2002, had no history of CVD and were undertreated. Of the 
565 participants starting statin treatment 389 (69%) were
overtreated according to the same guidelines. After projection on
the general Dutch population, the absolute costs for overtreat-
ment with statins in 2005 were estimated to be approximately
23 million Euros (Uncertainty limits (UL): 19–28 million Euro),
while the cost to eliminate undertreatment were also 23 million
Euros (UL: 19–28 million Euros). CONCLUSION: In conclu-
sion, when considering only drug costs reallocation of resources
used for statin treatment from those overtreated to those under-
treated could lead to a more efﬁcient use of resources.
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OBJECTIVES: To identify key factors determining therapeutic
decision making concerning coronary artery disease treatment in
the GPs’ and specialists’ practices. To establish role of economic
factors related. METHODS: A survey was conducted on the rep-
resentative sample of Polish physicians (184 GPs and 63 spe-
cialists in the outpatient clinics) dealing with coronary artery
disease (CAD) patients. Data were obtained with the aid of a
speciﬁc questionnaire, including 6 items completed by doctor.
RESULTS: Choosing the treatment for a CAD patient, 75% of
the GPs and specialists have taken drugs’ efﬁcacy into consider-
ation at ﬁrst. Safety of treatment (GPs 9.8% and specialists
12.7% respectively) and adherence to guidelines (9.2%; 9.5%)
were rarely considered as main factors. One third of the GPs and
specialists declared that unbearable drugs’ costs constituted the
most frequent reason for treatment discontinuation. The adverse
events (20.6% and 20.1%) and poli-therapy (20.6% and 19.6%)
were the next reasons cited. Treatment with the lowest priced
drugs (75%; 74%) and those medicines administered once a day
(75%; 71%) were described as two best ways of compliance
improvement. The most important factors leading to the change
of treatment were insufﬁcient efﬁcacy (88%) and adverse events
(81%). 70% of GPs and 74% of specialists declared, that every
third patient talked about economic issues of treatment (co-
payment, costs of diagnostic procedures and additional doctors’
consultations). Only 31.5% of the GPs and 41.3% of specialists
indicated an inﬂuence on the quality of life among the top three
most important factors determining a therapeutic decision.
CONCLUSIONS: Factors determining therapeutic decisions in
the CAD patients are quite similar among the GPs and special-
ists. Efﬁcacy and safety of therapy represented factors commonly
reported by the GPs as well as specialists. Unbearable cost of
pharmacotherapy was considered as one of the main causes
leading to treatment discontinuation and incompliance.
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OBJECTIVE: Regular testing of total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and triglycerides (TG)
is important for effective lipid management. Our objective was
to examine frequency of lipid testing and to assess predictors of
lipid testing frequency in UK patients newly initiated on statins
over a one year period. METHODS: This was a retrospective
cohort study performed using the UK General Practice Research
Database. Patients aged ≥35 years were included if they received
their ﬁrst ever statin between Jan-2000 and Dec-2004 and had
at least one TC, HDL-C or TG test conducted in the one year
period before statin initiation. Lipid tests performed after statin
initiation were counted until the earliest of either one-year
follow-up or statin discontinuation date plus 30 days. Poisson
regression was used to assess pre-initiation factors associated
with testing frequency for each lipid following statin initiation.
RESULTS: 57,296 patients received at least one TC, HDL-C or
TG at baseline and had one year of follow-up after statin initi-
ation. On average, patients received 1.3 ± 1.0 TC tests. However,
22.7% patients did not receive a single TC test after starting on
statins. The mean number of tests per patient for HDL-C and
TG was 0.9 ± 1.0 but 44.3% and 39.1% of patients did not
receive a single HDL-C and TG test, respectively. In the multi-
variate analysis, high cardiovascular risk [OR, 1.04; 95% CI,
1.01–1.07] and baseline TC ≥6.2 mmol/L [OR, 1.1; 95% CI,
1.06–1.18, compared with TC <5.0 mmol/L] were associated
with TC testing frequency. CONCLUSION: Higher cardiovas-
cular risk and higher baseline TC were associated with TC
testing within the ﬁrst year following statin initiation. Lack of
TC testing in approximately 2 in 10 UK patients during that
period and infrequent HDL-C and TG testing may prove as bar-
riers towards effective lipid management.
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OBJECTIVES: To develop a care map for Congestive Heart
Failure (CHF) in the UK, covering diagnosis, progression and
treatment of patients, focussing on points of interaction with the
UK NHS. METHODS: Available literature was searched for
national and local clinical guidelines and treatment algorithms
for CHF in the UK. Ten experts were consulted to validate and
complete the dataset. An interactive 1-year care map of CHF care
in the UK was then developed in MS Excel. New York Heart
Association (NYHA) bands I to IV were used to group patients
by disease severity and costs were estimated from an NHS per-
spective for 2005. Patient transition between hospital (including
readmissions), home and nursing home was modelled. Possible
surgical interventions were: heart transplantation, valve repair
and ICD. Summary statistics included: Patient disposition and
location after 1 year, total estimated costs (including where
accrued) and hospitalisation rates due to CHF. RESULTS: Over
one year, 878,000 existing CHF patients plus 63,000 new cases
would cost the NHS £896 million. The total spend (and per-
centage) on patients in hospital, at home and in nursing homes
were £550 million (62%), £298 million (33%) and £47 million
(5%) respectively. Surgery accounted for £13 million of hospital
costs. Of 941,000 CHF patients, 291,000 will be hospitalised
